GlassScriptPhysician profile
Faith Cutrona
NPI 1033358387
$8,954.25
in general payments reported to CMS, 2019-2025
34 companies · $1,183 in 2025
The $1,183 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,658 · 2022: $2,965 · 2023: $1,243 · 2024: $905 · 2025: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,322 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,322.05 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,375.67 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $865.09 | 2021-2025 | Evenity, Repatha, Krystexxa |
| Abbvie INC. | $756.40 | 2021-2023 | |
| Lilly USA, LLC | $719.93 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $523.21 | 2021-2025 | Airsupra, Breztri |
| Pfizer INC. | $489.16 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $481.01 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $328.80 | 2021-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $327.11 | 2021-2023 | Ajovy |
| Biohaven Pharmaceutical Holding Company LTD. | $251.55 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.38 | 2021-2023 | Synjardy |
| Antares Pharma, INC. | $195.40 | 2021-2023 | Tlando, Nocdurna, Xyosted |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $177.23 | 2022-2025 | Lifevest |
| Paratek Pharmaceuticals, INC. | $172.40 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $125.68 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Itamar Medical INC | $120.71 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.51 | 2021-2023 | Xifaxan, Trulance |
| Genentech USA, INC. | $104.01 | 2021-2022 | |
| Abbott Laboratories | $93.81 | 2021-2023 | Octrode |
| Arbor Pharmaceuticals, INC. | $73.01 | 2021-2022 | |
| Amarin Pharma, INC. | $72.11 | 2021 | |
| Glaxosmithkline, LLC. | $59.88 | 2021-2023 | Shingrix |
| Idorsia Pharmaceuticals US INC | $48.11 | 2023 | Quviviq |
| Alfasigma USA, INC. | $47.25 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $31.99 | 2021-2022 | |
| Axsome Therapeutics, INC. | $25.16 | 2023 | Auvelity |
| Hikma Pharmaceuticals USA | $23.36 | 2021 | |
| Eisai INC. | $23.22 | 2021 | |
| Ironwood Pharmaceuticals, INC | $23.10 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.24 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.44 | 2023 | |
| Acerus Pharmaceuticals Corporation | $13.08 | 2021 | |
| Vistapharm, INC. | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faith Cutrona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.